Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially ...

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing ...

Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an ...

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...

A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end ...